Executive Summary
| Company | Country - HQ | Principal officer - Role | Focus/ area of specialty | News flow | Financial performance (FY 2009) |
| ADImmune | Taiwan - Taipei | Ignatius Wei - President | vaccine development and commer- cialisation | n/a | private company |
| AnGes MG | Japan - Osaka | Ei Yamada - President and CEO | drug development | AnGes MG is granted a patent in Japan for a new decoy oligonucleotide (2009) | total revenue: Yen585 million |
| aRigen | Japan - Tokyo | Gensuke Tokoro - President and CEO | drug discovery and development | aRigen and CJ CheilJedang sign an agreement to jointly develop ARH-1029 for the treatment of peptic ulcer disease (2010) | private company |
| Astellas | Japan - Tokyo | Masafumi Nogimori - President and CEO | drug development and commer- cialisation | Astellas completes $ 4 billion acquisition of OSI Pharmaceuticals (2010) | net sales: Yen974.88 billion |
| Crystal Genomics | South Korea - Seoul | Dr Cho Joong Myung* - President and CEO | drug discovery and development | CrystalGenomics to merge with BexPharm, a South Korean speciality pharmaceutical company (2010) | private company |
| Daiichi Sankyo | Japan - Tokyo | Takashi Shoda - President and CEO | drug development and commer- cialisation | Daiichi Sankyo launches Rezaltas combination tablets for the treatment of hypertension in Japan (2010) | net sales: Yen952.1 billion |
| Eisai | Japan - Tokyo | Haruo Naito - President and CEO | drug development and commer- cialisation | Eisai establishes new sales subsidiary in Canada (2010) | net sales: Yen803 billion |
| Fujifilm | Japan - Tokyo | Shigetaka Komori - President and CEO | divisions for medical imaging and diagnostics | Fujifilm’s subsidiaries, Perseus Proteomics and Fujifilm RI Pharma, present the development of a new radiolabelled anticancer antibody to a meeting of the Society of Nuclear Medicine (2010) | revenue: Yen2,434 billion |
| Histostem | South Korea - Seoul | Dr Hoon Han - President | biotechnology | n/a | private company |
| Hutchison Medipharma ** | China - Shanghai | Dr Samantha Du - CEO | drug discovery and development | signs agreement with Ortho-McNeil-Janssen Pharmaceuticals to discover and develop therapeutics to treat inflammatory and immune diseases (2008) | sales: $111 million (parent company) |
| HUYA Bioscience | China - Shanghai and San Diego, US | Dr Mireille Gingras - CEO | biopharmaceutical development | Huya announces a strategic partnership with the School of Chinese Materia Medica of the Beijing University of Chinese Medicine (2010) | private company |
| Indofarma | Indonesia - Jakarta | P Sudibyo - Managing director | drug development and commer- cialisation | Indofarma and 3M Indonesia sign a partnership to market, distribute and sell 3M’s nitroglycerin transdermal patch system (2010) | private company |
| Innova Biotech | Thailand - Bangkok | n/a - n/a | immuno- diagnostics | n/a | private company |
| Kalbe Farma | Indonesia - Jakarta | Johannes Setijono - President and director | drug development and commer- cialisation | n/a | sales: Rupiah9,087 billion |
| LG Life Sciences | South Korea - Seoul | Kim In-Chull* - President and CEO | drug development and commer- cialisation | LG Life Sciences announces the discovery of new necrosis inhibitors (2009) | sales: Won327.3 billion |
| Macrogen | South Korea - Seoul | Seo Jeongsun - Chairman | biotechnology | Macrogen research team publishes a genome map of a Korean male in the journal Nature (2009) | sales: Won22.46 billion |
| Medigen Biotechnology | Taiwan - Taipei | Dr Stanley Chang* - Chairman and CEO | drug development and diagnostics | Medigen receives ASHI laboratory accreditation for HLA typing (2009) | n/a |
| Medipost | South Korea - Yongin-si | Jin Chang-Hyun - CEO | biotechnology | n/a | n/a |
| MerLion Pharma | Singapore - Singapore | Dr Tony Buss - President and CEO | contract research and drug development | MerLion and Chaperone Technologies collaborate on the development of new antimicrobials (2009) | private company |
| MicuRx/ Cumencor Pharma (MicuRx’s Chinese affiliate) | China - Shanghai and Hayward, CA, US | Dr Yuan Zhengyu - President and CEO | drug discovery and development | MicuRx and Cumenor Pharmaceuticals partner with Pfizer to discover and develop antibiotics for drug-resistant TB in China (2010); MicuRx raises $10 million in a series A financing round (2007) | private company |
| Moleac | Singapore - Singapore | David Picard - CEO | drug development and commer- cialisation | opens office in Paris, France (2009); launches NeuroAiD in Iran, Jordan, Pakistan and Thailand (2009) | private company |
| RNL Bio | South Korea - Seoul | Dr Ra Jeong-Chan - President | biotechnology | RNL Bio and Start Licensing settle patent disputes and conclude a licence agreement on animal cloning (2010) | private company |
| S*BIO | Singapore - Singapore | Dr Jan-Anders Karlsson*** - CEO | drug development | S*Bio presents positive safety and tolerability results for its novel oral JAK2 inhibitor SB1518 from a Phase I/II study for the treatment of myelofibrosis (2010) | private company |
| Shenzhen SiBiono GeneTech | China - Shenzhen | Dr Peng Zhaohin - Chairman and CEO | gene therapy | n/a | n/a |
| Shionogi | Japan - Osaka | Dr Isao Teshirogi - President | drug development and commer- cialisation | Shionogi announces the establishment of a new Japanese research subsidiary, Shionogi Techno Advance Research (2010) | net sales: Yen227.5 billion |
| Sinovac Biotech | China - Beijing | Dr Yin Weidong* - President and CEO | vaccine development and commer- cialisation | Sinovac completes $17.6 million buildings and land acquisition to expand vaccine production capacity (2010) | sales: $84.20 million |
| TaiGen Biotech | Taiwan - Taipei | Dr Hsu Ming-Chu* - Chairman, president and CEO | drug discovery | TaiGen raises $37 million in a series C financing round (2009) | private company |
| TaiMed Biologics | Taiwan - Taipei | James Chang - CEO | drug development | n/a | private company |
| Taiwan Biotech | Taiwan - Taoyuan City | n/a - n/a | drug development and commer- cialisation | n/a | private company |
| Takara Bio | Japan - Shiga | Koichi Nakao - President and CEO | biotechnology | Takara Bio executes a collaborative research agreement with the University of Pennsylvania to support an HIV gene therapy clinical trial in the US (2010) | net sales: Yen18,913 million |
| Takeda | Japan - Osaka | Yasuchika Hasegawa - President | drug development and commercialisation | Takeda plans to establish a new commercial subsidiary in South Korea (2010) | sales: Yen1,466 billion |
| UMN Pharma | Japan - Akita City | Dr Shu-Ichi Kanazashi - President and CEO | drug development and commer- cialisation | UMN Pharma and API Co announce formulation process collaboration for influenza vaccine candidate UMN-0501 (2010) | private company |
| United Laboratories (Unilab) | Philippines - Mandaluyong City | Jocelyn Campos-Hess - Chairperson | drug development and commer- cialisation | n/a | private company |
| Viromed | South Korea - Seoul | Dr Kim Sunyoung and Kim Yongsoo - Co-CEOs | drug development | Viromed completes merger with Helixir Co, a developer of phytotherapeutics (2009) | revenues: $7.66 million |
*Scrip Asia 100 ’Shining Star’; **Hutchinson China MediTech, part of Chi-Med; ***interviewed in Scrip Asia 100
Source: Scrip analysis
